Eliem Therapeutics Inc

NASDAQ ELYM

Download Data

Eliem Therapeutics Inc Accounts Payable Turnover Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending September 20, 2024

Eliem Therapeutics Inc Accounts Payable Turnover Ratio 1 year YoY Change (%) is NA for the Trailing 12 Months (TTM) ending September 20, 2024. The accounts payable turnover ratio measures the number of times a company pays off its accounts payable during a specific period. It is calculated by dividing the company's revenue by its accounts payable. This ratio indicates how efficiently a company manages its outstanding payments to suppliers and vendors. A higher turnover ratio suggests that the company is paying off its obligations quickly, while a lower ratio may indicate a slower payment process or potential liquidity issues. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Eliem Therapeutics Inc Accounts Payable Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.00, a 0.00% change year over year.
  • Eliem Therapeutics Inc Accounts Payable Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.00, a 0.00% change year over year.
  • Eliem Therapeutics Inc Accounts Payable Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.00.
NASDAQ: ELYM

Eliem Therapeutics Inc

CEO Mr. Robert W. Azelby M.B.A.
IPO Date Aug. 10, 2021
Location United States
Headquarters 23515 NE Novelty Hill Road, Redmond, WA, United States, 98053
Employees 9
Sector Healthcare
Industry Biotechnology
Description

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Similar companies

MNOV

MediciNova Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

HCWB

HCW Biologics Inc

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

CYT

Cyteir Therapeutics Inc

NA

NA

IPSC

Century Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email